NCT07308990 Limited Versus Extended Lymph Node Dissection During Radical Prostatectomy in Patients With Localized or Locally Advanced Prostate Cancer
| NCT ID | NCT07308990 |
| Status | Recruiting |
| Phase | — |
| Sponsor | N.N. Alexandrov National Cancer Centre |
| Condition | Prostate Cancer Patients Undergoing Radical Prostatectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2025-10-29 |
| Primary Completion | 2030-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2025-10-29 with a primary completion date of 2030-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized controlled study assessing outcome of low (no or limited) versus high (limited or extended) extent of lymph node dissection in addition to radical prostatectomy in patients with operable localized or locally advanced prostate cancer.
Eligibility Criteria
Inclusion Criteria: 1. Age over 18 years. 2. Histologically confirmed localized or locally advanced prostate cancer (adenocarcinoma without a neuroendocrine component). 3. No evidence of metastatic spread of the tumor 4. Local resectability of the tumor according to digital rectal examination and/or CT and/or MRI of the pelvis 5. Patients are suitable for radical prostatectomy based on their comorbidities and life expectancy. 6. Signed informed consent to participate in the study. Exclusion Criteria: 1. Presence of another active malignant invasive neoplasm. 2. Contraindication to pelvic lymph node dissection (e.g., history of radiation therapy to the pelvis). 3. The evidence of metastases in regional lymph nodes according to preoperative examination data (including PET/CT with PSMA). 4. Severe concomitant disease limiting participation in the study.
Frequently Asked Questions
Who can join the NCT07308990 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer Patients Undergoing Radical Prostatectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07308990 currently recruiting?
Yes, NCT07308990 is actively recruiting participants. Visit ClinicalTrials.gov or contact N.N. Alexandrov National Cancer Centre to inquire about joining.
Where is the NCT07308990 trial being conducted?
This trial is being conducted at Lyasny, Belarus.
Who is sponsoring the NCT07308990 clinical trial?
NCT07308990 is sponsored by N.N. Alexandrov National Cancer Centre. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.